Literature DB >> 12385702

Activity of GAR-936 and other antimicrobial agents against North American isolates of Staphylococcus aureus.

Donald E Low1, Barry N Kreiswirth, Karl Weiss, Barbara M Willey.   

Abstract

The comparative in vitro activity of GAR-936 and 12 other drugs against 602 North American isolates of methicillin-susceptible (MSSA) and methicillin-resistant (MRSA) Staphylococcus aureus was determined. The GAR-936 MICs ranged from 0.06 to 1.0 mg/l. The MIC(50)s and MIC(90)s were 0.12 and 0.25 mg/l for MSSA and 0.25 and 0.5 mg/l for MRSA. Copyright 2002 Elsevier Science B.V. and International Society of Chemotherapy

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12385702     DOI： 10.1016/s0924-8579(02)00132-2

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN： 0924-8579            Impact factor:   5.283


  6 in total

Review 1.  Tigecycline.

Authors:  James E Frampton; Monique P Curran
Journal:  Drugs       Date:  2005       Impact factor: 9.546

2.  Diagnostic PCR analysis of the occurrence of methicillin and tetracycline resistance genes among Staphylococcus aureus isolates from phase 3 clinical trials of tigecycline for complicated skin and skin structure infections.

Authors:  C Hal Jones; Margareta Tuckman; Anita Y M Howe; Mark Orlowski; Stanley Mullen; Karen Chan; Patricia A Bradford
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

3.  Tigecycline MIC testing by broth dilution requires use of fresh medium or addition of the biocatalytic oxygen-reducing reagent oxyrase to standardize the test method.

Authors:  Patricia A Bradford; Peter J Petersen; Mairead Young; C Hal Jones; Mark Tischler; John O'Connell
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

4.  Comparative in vitro antimicrobial activity of tigecycline, a new glycylcycline compound, in freshly prepared medium and quality control.

Authors:  Steven D Brown; Maria M Traczewski
Journal:  J Clin Microbiol       Date:  2007-05-09       Impact factor: 5.948

Review 5.  Antibiotics for treatment of resistant gram-positive coccal infections.

Authors:  Hossam Al-Tatari; Nahed Abdel-Haq; Pimpanada Chearskul; Basim Asmar
Journal:  Indian J Pediatr       Date:  2006-04       Impact factor: 5.319

6.  A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections [Study ID Numbers: 3074A1-301-WW; ClinicalTrials.gov Identifier: NCT00081744].

Authors:  María E Oliva; Arcot Rekha; Albert Yellin; Jacyr Pasternak; Maria Campos; Gilbert M Rose; Timothy Babinchak; Evelyn J Ellis-Grosse; Evan Loh
Journal:  BMC Infect Dis       Date:  2005-10-19       Impact factor: 3.090
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.